Vanguard Group Inc. Has $217.48 Million Holdings in Progyny, Inc. $PGNY

Vanguard Group Inc. raised its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 2.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,106,147 shares of the company’s stock after acquiring an additional 235,513 shares during the period. Vanguard Group Inc. owned about 11.75% of Progyny worth $217,484,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PGNY. Principal Financial Group Inc. raised its stake in shares of Progyny by 57.1% during the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after purchasing an additional 256,078 shares during the period. Cresset Asset Management LLC raised its stake in shares of Progyny by 715.3% during the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company’s stock valued at $1,871,000 after acquiring an additional 74,621 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Progyny in the second quarter worth about $327,000. Y Intercept Hong Kong Ltd boosted its position in shares of Progyny by 88.0% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock worth $1,236,000 after purchasing an additional 26,310 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its position in Progyny by 33.1% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after buying an additional 412,395 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PGNY has been the topic of a number of research analyst reports. Citigroup raised Progyny to an “outperform” rating in a report on Tuesday, January 20th. Canaccord Genuity Group boosted their target price on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research note on Tuesday, January 20th. Finally, Barclays began coverage on Progyny in a research report on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.20.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $17.69 on Monday. The firm’s 50 day simple moving average is $23.90 and its 200-day simple moving average is $23.11. The firm has a market cap of $1.53 billion, a PE ratio of 27.22, a price-to-earnings-growth ratio of 1.12 and a beta of 1.01. Progyny, Inc. has a one year low of $16.75 and a one year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS $0.48 vs. $0.38 est.; revenue $318.4M vs. ~$314M est.), showing year-over-year revenue growth. Read More.
• Positive Sentiment: Strong cash generation and shareholder returns: Progyny reported record $210.2M operating cash flow for the year and has repurchased ~6.5M shares under its authorization to date. Read More.
• Positive Sentiment: FY 2026 EPS guidance was raised above consensus (1.83–1.95 vs. ~1.55Street est.), indicating management expects better full‑year profitability despite near‑term revenue headwinds. Read More.
• Neutral Sentiment: Transcripts and slide deck from the earnings call are available for investors who want management detail on drivers (retention, pricing, membership growth) and cadence of benefits. Read More.
• Negative Sentiment: Near‑term revenue guidance disappointed: Q1 2026 revenue guidance ($319M–$332M) is below consensus (~$345M), which likely explains the sell‑off despite the EPS beat and stronger FY EPS outlook. Read More.
• Negative Sentiment: Short interest has risen materially (reported ~41% increase in shares sold short in February to ~4.0M shares, ~5.1% of float), increasing downside pressure and volatility. Read More.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.